EYEPOINT PHARMS
PharmaEYEPOINT PHARMS is a pharmaceutical company focused on Respiratory, Dermatology. Key products include DEXYCU KIT.
EYEPOINT PHARMS at a Glance
- Fast trial execution (18 months median completion)
EYEPOINT PHARMS's Key Drugs
EYEPOINT PHARMS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
EYEPOINT PHARMS's Recent FDA Approvals
New NDA/BLA approvals for EYEPOINT PHARMS over the last two years — novel drugs only, excluding generics and label supplements.
EYEPOINT PHARMS's Therapeutic Areas
EYEPOINT PHARMS's approved drugs and pipeline span 2 therapeutic areas, led by Respiratory and Dermatology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
EYEPOINT PHARMS's Top Competitors
EYEPOINT PHARMS's closest competitors by therapeutic-area and drug-target overlap include Bayer, PHARMACIA AND UPJOHN, and LEDERLE. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
EYEPOINT PHARMS Pipeline Snapshot
Active clinical trials for EYEPOINT PHARMS across all therapeutic areas, from ClinicalTrials.gov.
Phase 3 Readout Calendar Pro
3 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 3/10 completed
- • Speed: 18 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (1)
Company Info
- First Approval
- 2018-02-09
- Latest
- 2020-06-04
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges